JP2001502346A - 皮膚疾患の治療に用いる共役リノール酸の亜鉛塩 - Google Patents
皮膚疾患の治療に用いる共役リノール酸の亜鉛塩Info
- Publication number
- JP2001502346A JP2001502346A JP10519084A JP51908498A JP2001502346A JP 2001502346 A JP2001502346 A JP 2001502346A JP 10519084 A JP10519084 A JP 10519084A JP 51908498 A JP51908498 A JP 51908498A JP 2001502346 A JP2001502346 A JP 2001502346A
- Authority
- JP
- Japan
- Prior art keywords
- composition
- linoleic acid
- zinc salt
- conjugated linoleic
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000017520 skin disease Diseases 0.000 title claims abstract description 20
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 title claims description 44
- 150000003751 zinc Chemical class 0.000 title claims description 38
- 229940108924 conjugated linoleic acid Drugs 0.000 title claims description 37
- JBYXPOFIGCOSSB-GOJKSUSPSA-N 9-cis,11-trans-octadecadienoic acid Chemical compound CCCCCC\C=C\C=C/CCCCCCCC(O)=O JBYXPOFIGCOSSB-GOJKSUSPSA-N 0.000 title description 26
- 239000000203 mixture Substances 0.000 claims abstract description 48
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 14
- 201000011510 cancer Diseases 0.000 claims abstract description 14
- 201000004624 Dermatitis Diseases 0.000 claims abstract description 9
- 208000000453 Skin Neoplasms Diseases 0.000 claims abstract description 7
- 201000000849 skin cancer Diseases 0.000 claims abstract description 7
- 208000010668 atopic eczema Diseases 0.000 claims abstract description 6
- 201000004681 Psoriasis Diseases 0.000 claims abstract description 5
- JBYXPOFIGCOSSB-XBLVEGMJSA-N 9E,11E-octadecadienoic acid Chemical compound CCCCCC\C=C\C=C\CCCCCCCC(O)=O JBYXPOFIGCOSSB-XBLVEGMJSA-N 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 16
- 239000003814 drug Substances 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 8
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims description 7
- 235000020778 linoleic acid Nutrition 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 5
- 208000004898 Herpes Labialis Diseases 0.000 claims description 2
- 206010067152 Oral herpes Diseases 0.000 claims description 2
- 206010062639 Herpes dermatitis Diseases 0.000 claims 1
- 150000007513 acids Chemical class 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000006071 cream Substances 0.000 description 8
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical group [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 6
- ODNJVAVDJKOYFK-GRVYQHKQSA-L zinc;(9z,12z)-octadeca-9,12-dienoate Chemical compound [Zn+2].CCCCC\C=C/C\C=C/CCCCCCCC([O-])=O.CCCCC\C=C/C\C=C/CCCCCCCC([O-])=O ODNJVAVDJKOYFK-GRVYQHKQSA-L 0.000 description 6
- 239000011701 zinc Substances 0.000 description 5
- 229910052725 zinc Inorganic materials 0.000 description 5
- 208000003251 Pruritus Diseases 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 3
- 206010033372 Pain and discomfort Diseases 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- GKJZMAHZJGSBKD-UHFFFAOYSA-N (10E,12E)-Octadeca-9,11-dienoic acid Natural products CCCCCC=CC=CCCCCCCCCC(O)=O GKJZMAHZJGSBKD-UHFFFAOYSA-N 0.000 description 1
- GKJZMAHZJGSBKD-BLHCBFLLSA-N (10e,12e)-octadeca-10,12-dienoic acid Chemical compound CCCCC\C=C\C=C\CCCCCCCCC(O)=O GKJZMAHZJGSBKD-BLHCBFLLSA-N 0.000 description 1
- GKJZMAHZJGSBKD-ANYPYVPJSA-N 10-trans-12-cis-linoleic acid Natural products CCCCCC=C\C=C\CCCCCCCCC(O)=O GKJZMAHZJGSBKD-ANYPYVPJSA-N 0.000 description 1
- OYHQOLUKZRVURQ-UHFFFAOYSA-N 9,12-Octadecadienoic Acid Chemical compound CCCCCC=CCC=CCCCCCCCC(O)=O OYHQOLUKZRVURQ-UHFFFAOYSA-N 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- 206010067723 Skin plaque Diseases 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 210000003423 ankle Anatomy 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 230000005722 itchiness Effects 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/315—Zinc compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1. 少なくとも1種の共役リノール酸の亜鉛塩を含む皮膚疾患治療用組成物。 2. 皮膚疾患の治療法に使用される請求項1に従う組成物。 3. 皮膚疾患治療用薬剤の製造における、少なくとも1種の共役リノール酸の 亜鉛塩を含む組成物の使用。 4. 少なくとも1種の共役リノール酸の亜鉛塩を含む組成物を用いることか ら成る皮膚疾患治療用薬剤の製造方法。 5. 少なくとも1種の共役リノール酸の亜鉛塩を含む組成物を使用すること から成る皮膚疾患の治療方法。 6. 請求項1〜請求項5のいずれかに従う組成物または方法であって、組成物 が、少なくとも1種の共役リノール酸の亜鉛塩を少なくとも50%含むも の。 7. 請求項6に従う組成物または方法であって、組成物が、少なくとも1種 の共役リノール酸の亜鉛塩を少なくとも60%、70%または90%含むもの。 8. 請求項1〜請求項7のいずれかに従う組成物または方法であって、共役リ ノール酸が、9,11−オクタデカジエン酸および10,12−オクタデカジエ ン酸から成る群より選ばれるもの。 9. 請求項1〜請求項8のいずれかに従う組成物または方法であって、皮膚疾 患が、湿疹、乾癬、唇ヘルペスおよび皮膚炎から成る群より選ばれるもの 。 10.少なくとも1種の共役リノール酸の亜鉛塩を含む癌治療用組成物。 11.癌の治療法に使用される請求項10に従う組成物。 12.癌治療用薬剤の製造における、少なくとも1種の共役リノール酸の亜鉛塩 を含む組成物の使用。 13.少なくとも1種の共役リノール酸の亜鉛塩を含む組成物を用いることか ら成る癌治療用薬剤の製造方法。 14.少なくとも1種の共役リノール酸の亜鉛塩を含む組成物を使用すること から成る癌の治療方法。 15.請求項10〜請求項14のいずれかに従う組成物または方法であって、組成 物が、少なくとも1種の共役リノール酸の亜鉛塩を少なくとも50%含む もの。 16.請求項15に従う組成物または方法であって、組成物が、少なくとも1種 の共役リノール酸の亜鉛塩を少なくとも60%、70%または90%含むもの。 17.請求項10〜請求項16のいずれかに従う組成物または方法であって、共役 リノール酸が、9,11−オクタデカジエン酸および10,12−オクタデカジ エン酸から成る群より選ばれるもの。 18.請求項10〜請求項17のいずれかに従う組成物または方法であって、癌が 皮膚癌であるもの。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9621630.4 | 1996-10-17 | ||
GBGB9621630.4A GB9621630D0 (en) | 1996-10-17 | 1996-10-17 | Treatment of skin disorders |
PCT/GB1997/002854 WO1998017269A1 (en) | 1996-10-17 | 1997-10-16 | Use of zinc salts of conjugated linoleic acids to treat skin disorders |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2001502346A true JP2001502346A (ja) | 2001-02-20 |
JP4243353B2 JP4243353B2 (ja) | 2009-03-25 |
Family
ID=10801560
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51908498A Expired - Lifetime JP4243353B2 (ja) | 1996-10-17 | 1997-10-16 | 皮膚疾患の治療に用いる共役リノール酸の亜鉛塩 |
Country Status (10)
Country | Link |
---|---|
US (2) | US6300374B1 (ja) |
EP (1) | EP1014967B1 (ja) |
JP (1) | JP4243353B2 (ja) |
AT (1) | ATE311871T1 (ja) |
AU (1) | AU718611B2 (ja) |
DE (1) | DE69734838T2 (ja) |
ES (1) | ES2253772T3 (ja) |
GB (1) | GB9621630D0 (ja) |
NZ (1) | NZ334593A (ja) |
WO (1) | WO1998017269A1 (ja) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6019990A (en) * | 1997-11-21 | 2000-02-01 | Natural Nutrition Ltd. As | Conjugated linoleic acid delivery system in cosmetic preparations |
GB9828379D0 (en) * | 1998-12-22 | 1999-02-17 | Unilever Plc | Skin care composition |
GB9828380D0 (en) | 1998-12-22 | 1999-02-17 | Unilever Plc | Skin lightening composition |
EP1162934A4 (en) * | 1999-02-22 | 2005-01-26 | Eric F Bernstein | COMPOSITIONS AND METHODS FOR PREVENTING PHOTOVAGENING |
AU6402700A (en) * | 1999-07-09 | 2001-01-30 | Monsanto Company | Treatment of cyclooxygenase-2 mediated disorders using conjugated fatty acid compounds |
GB9918028D0 (en) * | 1999-07-30 | 1999-09-29 | Unilever Plc | Skin care composition |
GB9918025D0 (en) * | 1999-07-30 | 1999-09-29 | Unilever Plc | Skin care composition |
ITMI991894A1 (it) | 1999-09-09 | 2001-03-09 | Carlo Ghisalberti | Acido linoleico coniugato e trigliceride nuovi metodi di sintesi e d'uso |
FR2802099A1 (fr) * | 1999-12-08 | 2001-06-15 | Fabre Pierre Cosmetique | Thiosalicylate de zinc, compositions dermatologiques le contenant, en particulier sous la forme d'un dispositif auto-adhesif ainsi que le procede de preparation de ce dernier |
WO2001085161A1 (de) * | 2000-05-05 | 2001-11-15 | Fresenius Kabi Deutschland Gmbh | KOMBINATIONSPRÄPARAT AUS φ-3-FETTSÄUREN UND KONJUGIERTEN LINOLSÄUREN ZUR BEHANDLUNG IMMUNOLOGISCH GEPRÄGTER KRANKHEITSBILDER |
US20030143165A1 (en) * | 2002-01-25 | 2003-07-31 | Allan Evans | NSAID-containing topical formulations that demonstrate chemopreventive activity |
TW200407172A (en) * | 2002-10-17 | 2004-05-16 | Unilever Nv | Scalp treatment |
EP1583546B1 (en) | 2002-10-25 | 2019-06-19 | Precision Dermatology, Inc. | Modulation of zinc levels to improve tissue properties |
EP1761256A4 (en) * | 2004-05-11 | 2008-01-23 | Fonterra Corporate Res And Dev | CLA-ENRICHED MILK FAT AND USE THEREOF |
US7767713B2 (en) * | 2004-08-05 | 2010-08-03 | Palo Alto Investors | Linoleic acid active agents for enhancing probability of becoming pregnant |
NZ543486A (en) * | 2005-11-10 | 2009-03-31 | Fonterra Corporate Res And Dev | Compositions of CIS-9, trans-11 conjugated linoleic acid and vaccenic acid and uses thereof |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CZ4032U1 (cs) * | 1993-05-17 | 1995-10-25 | Miroslav Ing. Štol | Farmaceutická kompozice pro topickou zevní aplikaci |
GB9323808D0 (en) * | 1993-11-18 | 1994-01-05 | Alpha Healthcare Ltd | Composition containing zinc for the treatment of skin disorders |
US6025334A (en) * | 1994-04-28 | 2000-02-15 | Les Laboratoires Aeterna Inc. | Extracts of shark cartilage having anti-collagenolytic, anti-inflammatory, anti-angiogenic and anti-tumoral activities; process of making, methods of using and compositions thereof |
-
1996
- 1996-10-17 GB GBGB9621630.4A patent/GB9621630D0/en active Pending
-
1997
- 1997-10-16 DE DE69734838T patent/DE69734838T2/de not_active Expired - Lifetime
- 1997-10-16 WO PCT/GB1997/002854 patent/WO1998017269A1/en active IP Right Grant
- 1997-10-16 US US09/284,047 patent/US6300374B1/en not_active Expired - Lifetime
- 1997-10-16 JP JP51908498A patent/JP4243353B2/ja not_active Expired - Lifetime
- 1997-10-16 ES ES97909433T patent/ES2253772T3/es not_active Expired - Lifetime
- 1997-10-16 AU AU47119/97A patent/AU718611B2/en not_active Ceased
- 1997-10-16 EP EP97909433A patent/EP1014967B1/en not_active Expired - Lifetime
- 1997-10-16 AT AT97909433T patent/ATE311871T1/de not_active IP Right Cessation
- 1997-10-16 NZ NZ334593A patent/NZ334593A/xx unknown
-
2000
- 2000-05-09 US US09/568,305 patent/US6288115B1/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
DE69734838D1 (de) | 2006-01-12 |
DE69734838T2 (de) | 2006-08-17 |
GB9621630D0 (en) | 1996-12-11 |
EP1014967A1 (en) | 2000-07-05 |
EP1014967B1 (en) | 2005-12-07 |
AU4711997A (en) | 1998-05-15 |
WO1998017269A1 (en) | 1998-04-30 |
ES2253772T3 (es) | 2006-06-01 |
AU718611B2 (en) | 2000-04-20 |
JP4243353B2 (ja) | 2009-03-25 |
US6288115B1 (en) | 2001-09-11 |
ATE311871T1 (de) | 2005-12-15 |
NZ334593A (en) | 2000-01-28 |
US6300374B1 (en) | 2001-10-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4243353B2 (ja) | 皮膚疾患の治療に用いる共役リノール酸の亜鉛塩 | |
US4665063A (en) | Method of treating acne | |
US4654373A (en) | Pharmaceutical formulations containing coenzyme Q10 suitable for topic administration | |
DE3205504C2 (de) | Äußerlich anwendbares, Ibuprofen enthaltendes Arzneimittel | |
JPH0714873B2 (ja) | 局所性製薬組成物 | |
JPS60100517A (ja) | 放射線潰瘍治療剤および方法 | |
CN108853312A (zh) | 聚桂醇外用凝胶及其制备方法 | |
JPH0748328A (ja) | L−カルニチンのo−エステル類を含む皮膚病処置のための医薬組成物 | |
EP0836476B1 (en) | A COSMETIC COMPOSITION comprising the glycopropyl ester of retinoic acid FOR SKIN APPLICATIONS AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF skin diseases, TUMOROUS CELLS, BLADDER OR NERVE DISORDERS | |
US20200030398A1 (en) | Skin care composition | |
JP3041365B2 (ja) | シス−ウロカニン酸含有皮膚科学組成物 | |
US8586064B2 (en) | Treating eczema and/or psoriasis | |
CA1112164A (en) | Therapeutic selenium compositions and the use thereof | |
DE4022815A1 (de) | Topische verwendung von (omega)-3-fettsaeuren-zubereitungen fuer hauterkrankungen | |
WO2016144196A1 (en) | A pharmaceutical and/or cosmetic composition for treating skin diseases and damages, the process for preparing of the pharmaceutical and/or cosmetic composition and its use | |
CN110944649B (zh) | 鼠李糖及其衍生物作为抗真菌剂的用途 | |
JPH0259519A (ja) | 皮膚炎症治療剤 | |
WO2006119540A1 (en) | Preparation for treating psoriasis | |
WO1994002132A1 (en) | Treatment of skin diseases | |
CN105582062A (zh) | 一种苦荞麸皮提取物及包含该提取物的皮肤外用制剂 | |
BG65352B1 (bg) | Средство за лечение на псориазис | |
AU2023287536A1 (en) | A skin care composition | |
CN118948958A (zh) | 一种具有祛腐生肌、攻毒散结功效的中药组合物、软膏及其制备方法 | |
CN114146118A (zh) | 一种治疗带状疱疹的外用制剂及其制备方法 | |
JPH0522686B2 (ja) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20041004 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080617 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080916 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20081027 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081014 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20081209 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20090105 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120109 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130109 Year of fee payment: 4 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |